I see on their website that Sapacitabine demonstrated superior effacacy vs Gemcitabine or Gemzar for Liver Cancer. I don't see any clinical studies for Liver cancer. Is Cyclacel running or planning on conducting any studies for Liver Cancers?
Another point of interest, SAP is oral administration and has low toxicity. It is easily combined with many other regimens. This is not to be understated. There is a high short interest 1.2 M which I believe was largely acquired to drive the stock down for the April 5 calls to expire worthless . Now that entity needs to unwind that short position before the MDS news breaks. They will do whatever they can to exit this trade as low as possible.
They are studying SAP as an agent targeting BRCA mutated cancer lines which are found in multiple cancer types. It appears that these mutated cancers are "super responders " to SAP. Once SAP is approved for front line AML, SAP will be used for multiple off label cancer uses. AML is the low hanging fruit and the fastest route to approval since survival is so limited. I also believe the final phase 2 data for MDS will position SAP for possible accelerated approval.
One of the main problems in Cancer Research is that these scientists or researches need to figure out why drugs work so well on 30-35% of cancer patients...they need to figure out what genotypes will fit best.
This company is totally undervalued.
CTIX has a drug that is supposed to work with apoptosis, and these drugs can be used in almost 50% of all cancers. Their Market Cap is over $100 Million and they are still cohorting phase I.
If Sapacitabine was that effective in preventing the spreading of liver cancer, they need to focus on this also.
The problem seems to be that they are trying to do too many things at once.
I am positive that Sapacitabine can be approved and be an excellent revenue producer. I bet their cash burn rate is high...haven't read the recent 10k yet, but with all these trials?